Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 19/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 19/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 19/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 19/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 19/20 | 1.00 |
| ▸ | DRD2 | P14416 | 14/20 | 1.00 |
| ▸ | DRD4 | P21917 | 14/20 | 1.00 |
| ▸ | DRD3 | P35462 | 14/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 3/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 3/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 3/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100746 | 1.00 | CHRM2 (1.00) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2149709 | 0.90 | CHRM5 (0.81) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL27074530 | 0.88 | CHRM1 (0.98) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL30777193 | 0.87 | CHRM1 (0.89) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL22077888 | 0.87 | CHRM1 (0.89) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4103777 | 0.86 | CHRM1 (0.75) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4097774 | 0.86 | CHRM1 (0.75) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4097069 | 0.85 | CHRM1 (0.74) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4095226 | 0.85 | CHRM1 (0.74) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4089899 | 0.85 | CHRM1 (0.74) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024100285-A1 | TREATMENT OF A COGNITIVE DISORDER WITH AN AGENT THAT INCREASES THE EXCITABILITY OF THE CLAUSTRUM | UNIVERSITÉ DE GENÈVE (CH) | 2024-05-16 | — | — | WO | claimed |
| US-20220347170-A1 | Method of Reducing Brow Ache | LENZ THERAPEUTICS OPERATIONS, INC. | 2022-11-03 | — | — | US | claimed |
| WO-2022232205-A1 | A METHOD OF REDUCING BROW ACHE | LENZ THERAPEUTICS, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| EP-3310336-B1 | OPHTHALMOLOGICAL COMPOSITION COMPRISING ACECLIDINE AND MANNITOL FOR USE IN THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260098245-A1 | Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-04-09 | — | — | US | disclosed |
| US-12590297-B2 | Differentiation method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-03-31 | — | — | US | disclosed |
| US-20260069533-A1 | METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12533347-B2 | Compositions and methods for storage stable ophthalmic drugs | LENZ THERAPEUTICS OPERATIONS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250352529-A1 | COMBINED USE OF M1 MUSCARINIC RECEPTOR AGONISTS AND M3 MUSCARINIC RECEPTOR ANTAGONISTS TO TREAT CANCER | US GOV VETERANS AFFAIRS (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4634193-A1 | SUBSTITUTED DIHYDROPYRROLO[3, 4-D]PYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Karuna Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20220218874-A1 | COMPOSITIONS AND METHODS OF MODULATING ENDOCHONDRAL OSSIFICATION AND BONE FORMATION | UNIV CASE WESTERN RESERVE (US) | 2022-07-14 | — | — | US | disclosed |
| US-11344538-B2 | Methods for the treatment of myopia | LENZ THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220125779-A1 | Compositions and Methods for Treating Traumatic Brain Injury | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | disclosed |
| WO-2022081204-A1 | COMPOSITIONS AND METHODS FOR STORAGE STABLE OPHTHALMIC DRUGS | PRESBYOPIA THERAPIES, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20220105090-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE CONDITIONS | LENZ THERAPEUTICS, INC. | 2022-04-07 | — | — | US | disclosed |
| US-11273150-B2 | Compositions and methods for the treatment of presbyopia | LENZ THERAPEUTICS, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220054462-A1 | SALIVARY GLAND REGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-24 | — | — | US | disclosed |
| US-20220031608-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA | LENZ THERAPEUTICS OPERATIONS, INC. | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069533-A1 | METHODS FOR THE TREATMENT OF PRESBYOPIA | CHRM2, ADRB2, CHRM3 | CHRM2 1/4885CHRM4 4/4885CHRM5 7/4885 |
| US-20260098245-A1 | Differentiation Method | GAPDH, ALPG, PYGL | CHRM2 3365/4885CHRM4 2430/4885CHRM5 3149/4885 |
| US-12533347-B2 | Compositions and methods for storage stable ophthalmic drugs | PDE6C, PDE6A, PDE6B | CHRM2 143/4885CHRM4 201/4885CHRM5 214/4885 |
| US-12590297-B2 | Differentiation method | WNT3A, SFRP1, WNT1 | CHRM2 3473/4885CHRM4 3391/4885CHRM5 3991/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | CHRM2 2/4885CHRM4 6/4885CHRM5 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.